Drug combo increases progression-free survival in advanced breast cancer

Article

Combination treatment with everolimus and the estrogen-blocker exemestane extended progression-free survival by as much as 7 months in postmenopausal women with advanced breast cancer resistant to hormone therapy, according to data from a clinical trial presented at the European Multidisciplinary Cancer Congress in Stockholm. MORE

Combination treatment with everolimus and the estrogen-blocker exemestane extended progression-free survival by as much as 7 months in postmenopausal women with advanced breast cancer resistant to hormone therapy, according to data from a clinical trial presented at the European Multidisciplinary Cancer Congress in Stockholm.

The phase III, randomized, double-blind, placebo-controlled, multicenter study, known as BOLERO-2 (Breast cancer trials of OraLEveROlimus-2), evaluated the efficacy of everolimus in 724 patients from 24 countries (average age 62 years) with advanced breast cancer resistant to aromatase inhibitors.

Investigators found that women with ER+HER2 advanced breast cancer treated with everolimus and exemestane had progression-free survival of 6.9 months compared with 2.8 months in women treated with exemestane alone-a 57% improvement. The trial was stopped early after a central review committee’s independent analysis found that the combination therapy extended progression-free survival by 10.6 months compared to 4.1 months for exemestane-a 64% improvement.

Everolimus targets mTOR, a protein that regulates tumor cell division, blood vessel growth, and cell metabolism. Resistance to hormonal therapy in breast cancer has been linked to overactivation of the mTOR pathway.

Side effects of the combination therapy were consistent with those reported for everolimus and didn’t worsen quality of life for patients. The most common grade 3 or 4 adverse effects reported were stomatitis, anemia, dyspnea, hyperglycemia, fatigue, noninfectious pneumonitis, and increased liver enzyme levels.

Read other articles in this issue of Special Delivery.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.